May 1, 2024Open Access

Figure S12 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

MAMinae AnSamsung Medical Center AMArnav MehtaMassachusetts General Hospital BMByung‐Hoon MinKia Motors (South Korea)

Key Points

Key points are not available for this paper at this time.

Abstract

Figure S12. Mean usage of stromal cNMF programs per stromal cell subset at (A) baseline, (B) post-chemotherapy (FU1) and (C) post-immunotherapy (FU2).

AI에게 질문

Bookmark

View Full Paper

Cite This Study

An et al. (Wed,) studied this question.

synapsesocial.com/papers/68e6c4b3b6db643587643671 https://doi.org/https://doi.org/10.1158/2159-8290.25729026.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
2Figure S11 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
3Figure S13 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
4Figure S14 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
5Figure S21 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024

AI에게 질문

Bookmark

View Full Paper